AWARE INC /MA/ — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that AWARE INC /MA/ filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $3.29M | Feb 28, 2018 |
| FY2017 | Sep 30, 2017 | $5.91M | Feb 28, 2018 |
| FY2017 | Jun 30, 2017 | $2.75M | Feb 28, 2018 |
| FY2017 | Mar 31, 2017 | $4.35M | Feb 28, 2018 |
| FY2017 | Dec 31, 2016 | $3.93M | Feb 28, 2018 |
| FY2017 | Sep 30, 2016 | $5.90M | Feb 28, 2018 |
| FY2017 | Jun 30, 2016 | $6.90M | Feb 28, 2018 |
| FY2017 | Mar 31, 2016 | $4.83M | Feb 28, 2018 |
| FY2016 | Dec 31, 2015 | $6.95M | Feb 10, 2017 |
| FY2016 | Sep 30, 2015 | $4.04M | Feb 10, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.87M) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | ($4.43M) | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | ($7.31M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($1.73M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | ($5.82M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($7.61M) | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | ($8.34M) | Feb 17, 2021 |
| FY2018 | Dec 31, 2018 | $639.0K | Feb 19, 2019 |
| FY2018 | Sep 30, 2018 | $1.28M | Feb 19, 2019 |
| FY2018 | Jun 30, 2018 | ($188.0K) | Feb 19, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.56M) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | ($5.55M) | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | ($8.54M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($2.22M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | ($6.10M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($9.42M) | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | ($4.18M) | Feb 17, 2021 |
| FY2018 | Dec 31, 2018 | $343.0K | Feb 19, 2019 |
| FY2018 | Sep 30, 2018 | $1.14M | Feb 19, 2019 |
| FY2018 | Jun 30, 2018 | ($381.0K) | Feb 19, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.30M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $7.76M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $9.12M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $9.23M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $9.26M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $9.09M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $7.93M | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | $7.11M | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $7.77M | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $6.94M | Feb 28, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.40M) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | ($3.16M) | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $1.82M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($5.04M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | ($6.23M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($5.27M) | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | ($2.95M) | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | $660.0K | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $3.67M | Feb 19, 2019 |
| FY2016 | Dec 31, 2016 | $3.81M | Feb 10, 2017 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $165.0K | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $45.0K | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $16.0K | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $730.0K | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $27.0K | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $484.0K | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $111.0K | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | $206.0K | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $82.0K | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $87.0K | Feb 28, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $37.20M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $42.64M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $46.30M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $51.19M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $48.37M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $51.63M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $57.56M | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | $66.44M | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $65.04M | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $61.98M | Feb 28, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.14M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $30.90M | Mar 6, 2026 |
| FY2025 | Dec 31, 2023 | $34.30M | Mar 6, 2026 |
| FY2024 | Dec 31, 2022 | $40.21M | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | $41.52M | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | $45.67M | Mar 15, 2023 |
| FY2021 | Dec 31, 2019 | $53.44M | Mar 15, 2022 |
| FY2020 | Dec 31, 2018 | $61.90M | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | $60.53M | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $59.00M | Feb 19, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.12M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $3.12M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $3.12M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $3.12M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $3.12M | Mar 15, 2023 |
| FY2022 | Dec 31, 2020 | $1.65M | Mar 15, 2023 |
| FY2020 | Dec 31, 2019 | $0 | Feb 17, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($75.82M) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | ($69.94M) | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | ($65.51M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($58.20M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | ($56.47M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($50.65M) | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | ($43.03M) | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | ($34.69M) | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | ($35.93M) | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | ($42.85M) | Feb 28, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.27M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $12.97M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $10.00M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $11.75M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $29.96M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $38.57M | Mar 15, 2022 |
| FY2021 | Dec 31, 2019 | $47.74M | Mar 15, 2022 |
| FY2020 | Dec 31, 2018 | $51.61M | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | $51.61M | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $51.91M | Feb 19, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Feb 17, 2021 |
| FY2018 | Dec 31, 2018 | 0 | Feb 19, 2019 |
| FY2018 | Sep 30, 2018 | 0 | Feb 19, 2019 |
| FY2018 | Jun 30, 2018 | 0 | Feb 19, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Feb 17, 2021 |
| FY2018 | Dec 31, 2018 | 0 | Feb 19, 2019 |
| FY2018 | Sep 30, 2018 | 0 | Feb 19, 2019 |
| FY2018 | Jun 30, 2018 | 0 | Feb 19, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 21.44M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | 21.10M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | 21.02M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | 21.09M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | 21.61M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | 21.38M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | 21.44M | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | 21.52M | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | 21.49M | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | 22.37M | Feb 28, 2018 |